Organogenesis (ORGO)
(Delayed Data from NSDQ)
$4.50 USD
-0.03 (-0.66%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.71 +0.21 (4.67%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Organogenesis has a market cap of $574.65M, which represents its share price of $4.53 multiplied by its outstanding shares number of 126.85M. As a small-cap company, ORGO's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ORGO 4.50 -0.03(-0.66%)
Will ORGO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ORGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORGO
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
ORGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
Bioventus (BVS) Matches Q3 Earnings Estimates
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock
Other News for ORGO
MiMedx price target raised by $1 at Cantor Fitzgerald, here's why
Biggest stock movers Tuesday: NVDA, TTD, STT, WFC and more
Organogenesis (ORGO) Supports New CMS Payment Proposal for 2026 | ORGO Stock News
ORGO: Cantor Fitzgerald Reiterates Overweight Rating with $7 Target | ORGO Stock News
Video: Why Organogenesis And MiMedx Are Sinking Today